IP Group PLC
IPO.UK
$0.59
Closing
▲2.37%
1D
▼-18.24%
YTD
Market cap
$603.90M
52 week high
$0.82
52 week low
$0.49
Volume
796,995
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$603.90M
Analysts' Rating
STRONG BUY
Price Target (Mean)
1.59903693
Total Analysts
0
P/E
Operating Margin
0.00%
Beta
1.73
Revenue Growth (Annual)
-100.66%
52 week high
$0.82
52 week low
$0.49
Div. Yield
2.74%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
IP Group PLC is a United Kingdom-based company that develops and supports businesses in deeptech, life sciences and cleantech. The Company also supports innovation emerging in universities and research institutions. The Company’s segments include Venture capital investing: Life Sciences, Venture capital investing: Deeptech, Venture capital investing: Cleantech, Venture capital investing: Other, and Third party fund management. Its Deeptech team focuses investment across four technology subsectors underpinned by global societal needs and macroeconomic trends. Its Cleantech platform, Kiko Ventures, is investing in assets that address the global climate challenge, targeting innovators that are creating scalable climate technology solutions. Its Life Sciences team focuses on curing and preventing disease. The Company’s portfolio includes Akamis Bio, Crescendo Biologics, Artios Pharma, First Light Fusion, Istesso, Featurespace, Hinge Health, Mission Therapeutics, and others.
